StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SNOA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.19 | $1.09 | -8.40% | 0.2M |
| 05-18 | $1.13 | $1.03 | -8.85% | 0.3M |
| 05-19 | $1.03 | $1.01 | -1.94% | 0.1M |
| 05-20 | $1.02 | $1.07 | +4.73% | 0.5M |
| 05-21 | $1.10 | $1.06 | -3.64% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $13.97M | $9.62M | $4.01M | $14.29M |
Operating Income | $-2.11M | $-1.43M | $-1.09M | $-3.71M |
Net Income | $-2.59M | $-534.00K | $-1.24M | $-3.46M |
EPS (Diluted) | $-1.56 | $-1.08 | $-0.76 | $-2.79 |
Total Assets | $13.62M | $13.86M | $14.59M | $13.69M |
Total Liabilities | $10.19M | $10.07M | $10.54M | $9.28M |
Cash & Equivalents | $2.56M | $3.04M | $3.60M | $5.37M |
Free Cash Flow OCF − CapEx | $-3.58M | $-2.77M | $-2.12M | $-168.00K |
Shares Outstanding | 1.73M | 1.65M | 1.64M | 1.63M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.